The U.S. Food and Drug Administration (FDA) has partnered with SAS, a market leader in advanced analytics software for four decades now and just inked a deal to extend that relationship. Committing up to $49.9 million in a Blanket Purchase Agreement (BPA), SAS will now support bold digital transformation efforts ongoing at the FDA. For example, the FDA is expanding its capabilities in natural language processing, AI, and machine learning capabilities via the SAS® Viya® platform with the goal to support the FDA’s mission as an essential public health agency.
Initial initiatives involve the FDA’s Center for Drug Evaluation and Research (CDER) and include:
- Advance CDER’s initiative to modernize drug regulatory programs
- Provide analytically driven drug manufacturing facility surveillance
- Better fulfill the center’s mission through other key initiatives
A longtime customer with a large and experienced SAS user community and many mission-critical SAS applications, the FDA will take advantage of the BPA to consolidate and expand its use of SAS utilizing the SAS Platform powered by SAS Viya, the company’s flagship cloud-based AI and machine learning platform. SAS will embed analytics experts within the FDA to help manage and identify modernization opportunities, within CDER and other areas of the agency.
“We are in a new era of drug regulation,” said SAS CEO Jim Goodnight. “By unleashing the power of SAS’ most advanced technologies, we can work together to help the FDA find the perfect combination of speed, efficacy and safety when it comes to getting lifesaving drugs to Americans.”
The BPA builds on decades of collaboration between the FDA, SAS and US Department of Health and Human Services (HHS). HHS uses SAS software extensively in several other agencies, including Centers for Disease Control and Prevention, National Institutes of Health, and Centers for Medicare and Medicaid Services. SAS is used in numerous applications for disease surveillance, food and drug safety, combatting the opioid crisis, Medicare fraud and abuse, and other enterprise performance management initiatives throughout HHS.